BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 7, 2026
Home » Topics » Disease categories and therapies » Infection

Infection
Infection RSS Feed RSS

Globe and China flag

China slashes tariffs on some medical devices

Jan. 9, 2026
By Tamra Sami
Beginning Jan. 1, 2026, China will apply provisional import tariff rates lower than the most-favored-nation rates on 935 items, the State Council announced. The move aims to boost collaboration between domestic and international sectors, and to leverage resources of both to expand the supply of high-quality goods.
Read More
Wood mouse in the snow

Refining, like reducing and replacing, can improve animal research

Jan. 9, 2026
By Anette Breindl
No Comments
The concept of the 3 Rs – reducing, refining and replacing animal research – has been championed since the 1950s, when William Russel and Rex Burch argued in their book “The Principles of Humane Experimental Technique” that the 3 Rs could simultaneously improve the treatment of research animals and advance the quality of scientific and medical research and testing. Current standard practices of animal research undeniably cause animal suffering at the same time that they have prioritized replicability over translatability.
Read More
Infection

Humanized N-hRSV mAbs show protective preclinical efficacy

Jan. 9, 2026
No Comments
Human respiratory syncytial virus (hRSV) represents a major global health burden and is a leading cause of severe respiratory disease, particularly among preterm infants. Despite extensive efforts to prevent hRSV infection, currently approved monoclonal antibody (mAb) therapies have been exclusively designed to target its surface fusion or pre-fusion protein (F-hRSV).
Read More
Infection

New 3CLpro inhibitors disclosed in Nxera Pharma patent

Jan. 8, 2026
Nxera Pharma UK Ltd. has divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Read More
Wood mouse in the snow
Drug design, drug delivery & technologies

Refining, like reducing and replacing, can improve animal research

Jan. 8, 2026
By Anette Breindl
No Comments
The concept of the 3 Rs – reducing, refining and replacing animal research – has been championed since the 1950s, when William Russel and Rex Burch argued in their book “The Principles of Humane Experimental Technique” that the 3 Rs could simultaneously improve the treatment of research animals and advance the quality of scientific and medical research and testing. Current standard practices of animal research undeniably cause animal suffering at the same time that they have prioritized replicability over translatability.
Read More
3D print imagery of hepatitis B virus

GSK’s hep B approach hits functional cure goal in pivotal trials

Jan. 7, 2026
By Jennifer Boggs
No Comments
As widely expected, GSK plc and Ionis Pharmaceuticals Inc. reported positive findings from two pivotal trials testing bepirovirsen in chronic hepatitis B, showing the antisense oligonucleotide therapy achieved a statistically and clinically meaningful functional cure rate, indicating a potential transition in CHB treatment beyond the current viral suppression-focused standard of care.
Read More
U.S. vaccine illustration

Industry considering options amid US vaccine upheaval

Jan. 7, 2026
By Mari Serebrov
No Comments
The chaos Health and Human Services Secretary Robert Kennedy has injected into the U.S. vaccine market could have long-term consequences as vaccine makers reevaluate business decisions and pipelines.
Read More
Immune

Cansino’s PCV24 gains clinical trial clearance in China

Jan. 7, 2026
No Comments
Cansino Biologics Inc. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for the company’s 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (PCV24).
Read More

US vaccine schedule slashed to international standards

Jan. 5, 2026
By Mari Serebrov
No Comments
With the stroke of a pen and no input from the CDC’s Advisory Committee for Immunization Practices, acting CDC Director Jim O’Neill cut the number of vaccines the agency routinely recommends for children to 11 on Jan. 5, down from 17 in 2024.
Read More
Infection

New DHODH inhibitors for malaria disclosed in patent

Dec. 29, 2025
Medicines for Malaria Venture and The University of Texas System have divulged dihydroorotate dehydrogenase (DHODH) (Plasmodium falciparum and Plasmodium vivax) inhibitors reported to be useful for the treatment of malaria.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 1642 1643 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 6, 2025.
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Brain illustrated with pills

    Serotonin receptor modulators for the treatment of OUD

    BioWorld Science
    Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
  • Liver anatomy illustration

    KLF15 shows potential as marker, target for cholangiocarcinoma

    BioWorld Science
    Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing